Data on prior pegylated liposomal doxorubicin (PLD) treatment in recurrent ovarian cancer: Post-hoc data analysis from the phase 3 randomized, open-label study comparing trabectedin and PLD versus PLD alone in patients with recurrent ovarian cancer
Bradley J. Monk,
Thomas J. Herzog,
George Wang,
Spyros Triantos,
Scott Maul,
Roland Knoblauch,
Tracy McGowan,
Waleed S.W. Shalaby,
Robert L. Coleman
Affiliations
Bradley J. Monk
Arizona Oncology (US Oncology Network), University of Arizona, Creighton University, Phoenix, AZ, United States; Corresponding author.
Thomas J. Herzog
University of Cincinnati Cancer Center, University of Cincinnati, Cincinnati, OH, United States
George Wang
Janssen Research & Development, Spring House, PA, United States
Spyros Triantos
Janssen Research & Development, Spring House, PA, United States
Scott Maul
Janssen Research & Development, Los Angeles, CA, United States
Roland Knoblauch
Janssen Research & Development, Spring House, PA, United States
Tracy McGowan
Janssen Scientific Affairs, LLC, Horsham, PA, United States
Waleed S.W. Shalaby
Janssen Scientific Affairs, LLC, Horsham, PA, United States
Robert L. Coleman
The University of Texas MD Anderson Cancer Center, Houston, TX, United States
The data presented herein are supplementary to our published primary article “A phase 3 randomized, open-label, multicenter trial for safety and efficacy of combined trabectedin and pegylated liposomal doxorubicin therapy for recurrent ovarian cancer”[1]. The exploratory analysis evaluated the impact of prior pegylated liposomal doxorubicin (PLD) therapy in patients who participated in a randomized, open-label study comparing combination therapy of trabectedin and PLD vs PLD alone in third-line recurrent ovarian cancer (ROC). These exploratory analyses showed that prior treatment with PLD in ROC does not impact the response and survival rates nor does it increase toxicities or negatively influence survival and response rates in both treatment groups.
